Life Science Venture Capital
We believe that rare diseases accord us a great opportunity to create a path worthy and beneficial to society.
Society realizes the drama of rare diseases. Chiesi Ventures want to be instrumental in funding great research and development opportunities for therapies that can provide a hope for the patients and their families.
Focused on rare diseases
We recognize that rare diseases are global in nature from diagnosis to clinical development.
To initiate a global presence and address this concern, Chiesi Ventures established offices in Italy and US to evaluate opportunities and assist companies in the US and EU.
In US and Europe
Chiesi Ventures is a venture capital firm focused on the area of rare and orphan disorders. Our goal is to complement the strategic interest of the Chiesi Group by investing in early stage development opportunities. Chiesi Ventures also aim to accelerate the expansion of the Chiesi network in EU and the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases.
On September 2, 2014, Chiesi Ventures and Pappas Capital announced a strategic collaboration.
With the deal, Chiesi Ventures is able to leverage A. M. Pappas & Associates’ expertise and network to access and assess deals and opportunities, lead investments and manage transactions
ABOUT CHIESI VENTURES
Chiesi Ventures is unique in its focus: improving quality of diagnosis, disease management, care and therapy to all patients affected by rare diseases.
We are creating a portfolio of companies focused specifically on the field of rare diseases but with complementary capabilities and missions.
THE BURDEN OF RARE DISEASES
Rare diseases are conditions affecting less than 200,000 people in the US and less than five (5) in 10,000 according to the definition adopted by the European Medicines Agency.
An estimated 6,000 - 7,000 rare diseases have been diagnosed so far.
Collectively, an estimated 30 million people are affected by a rare disease in Europe with a similar occurrence in the US. 80% of rare diseases have been described as genetic in nature.
Chiesi Ventures invests in Glycomine
November 16, 2016